Q2 EPS Forecast for Axsome Therapeutics Raised by Analyst

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Stock analysts at HC Wainwright upped their Q2 2026 earnings per share estimates for Axsome Therapeutics in a research note issued to investors on Monday, January 5th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.65 per share for the quarter, up from their previous forecast of $0.46. HC Wainwright currently has a “Buy” rating and a $200.00 price target on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q3 2026 earnings at $1.50 EPS, Q4 2026 earnings at $2.01 EPS and FY2026 earnings at $3.72 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The firm had revenue of $170.99 million for the quarter, compared to analysts’ expectations of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. Axsome Therapeutics’s quarterly revenue was up 63.2% compared to the same quarter last year.

Several other research firms have also commented on AXSM. Oppenheimer reaffirmed an “outperform” rating and set a $220.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Needham & Company LLC reiterated a “buy” rating and set a $225.00 price objective on shares of Axsome Therapeutics in a research report on Monday. Royal Bank Of Canada lifted their target price on Axsome Therapeutics from $189.00 to $198.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 4th. UBS Group raised their price objective on Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $192.35.

Axsome Therapeutics Trading Down 1.8%

Shares of NASDAQ AXSM opened at $167.55 on Wednesday. The firm’s 50 day moving average price is $150.22 and its 200-day moving average price is $127.35. Axsome Therapeutics has a 52-week low of $79.19 and a 52-week high of $184.40. The company has a market cap of $8.45 billion, a PE ratio of -35.88, a P/E/G ratio of 9.00 and a beta of 0.44. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57.

Insiders Place Their Bets

In other news, Director Mark E. Saad sold 37,577 shares of the company’s stock in a transaction on Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the completion of the sale, the director owned 10,002 shares of the company’s stock, valued at $1,652,130.36. This represents a 78.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Herriot Tabuteau sold 31,261 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $170.38, for a total value of $5,326,249.18. Following the transaction, the chief executive officer owned 7,229 shares in the company, valued at approximately $1,231,677.02. This represents a 81.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 420,903 shares of company stock worth $63,552,838 in the last three months. 22.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of AXSM. Vident Advisory LLC acquired a new position in Axsome Therapeutics in the 1st quarter valued at about $360,000. AQR Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 52.7% in the first quarter. AQR Capital Management LLC now owns 58,363 shares of the company’s stock valued at $6,807,000 after acquiring an additional 20,152 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Axsome Therapeutics by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock worth $2,557,000 after purchasing an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp increased its position in Axsome Therapeutics by 2,407.9% in the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after acquiring an additional 7,320 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Axsome Therapeutics by 38.7% during the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after purchasing an additional 84,151 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised its 2026 earnings estimates (Q2/Q3/Q4 and FY2026 to a combined $3.72 EPS) and reiterated a Buy with a $200 price objective, signaling expectations for stronger near‑term profitability and supporting higher valuation.
• Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can help underpin demand for the shares. Read More.
• Positive Sentiment: Market commentary points to late‑2025 FDA moves — acceptance of a supplemental filing for AXS‑05 (agitation in Alzheimer’s) and FDA support for an NDA filing for AXS‑12 (narcolepsy) — expanding potential indications and revenue runway. Read More.
• Neutral Sentiment: Morgan Stanley reaffirmed an “equal weight” view but lifted its price target to $204 (from $196), implying upside vs. current levels but stopping short of a buy endorsement. Read More.
• Negative Sentiment: Insider selling: CEO Herriot Tabuteau sold a large block of shares across Jan. 5–7 (totaling roughly 139,414 shares over multiple transactions), leaving him with ~7,229 shares — a >90% reduction in his direct holding. Large, concentrated CEO sales can create near‑term supply pressure and raise investor concerns about optics or liquidity needs. Read More.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.